برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Recarbrio (imipenem, cilastatin, and relebactam) for Injection Date of Approval: July 16, 2019 Company: Merck Treatment for: Urinary Tract Infection, Intraabdominal Infection, Nosocomial Pneumonia Recarbrio (imipenem, cilastatin, and relebactam) is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adults. https://t.me/ppdprogram

➡️AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: July 15, 2019 Treatment for: Asthma AirDuo Digihaler (fluticasone propionate and salmeterol) is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) combination therapy for the treatment of asthma in patients aged 12 years and older. https://t.me/ppdprogram

➡️Katerzia (amlodipine benzoate) Oral Suspension Date of Approval: July 8, 2019 Company: Silvergate Pharmaceuticals, Inc. Treatment for: High Blood Pressure, Coronary Artery Disease Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults. https://t.me/ppdprogram

➡️Myxredlin (insulin human in sodium chloride) Injection Date of Approval: June 20, 2019 Company: Baxter International Inc. Treatment for: Diabetes, Type 1, Diabetes, Type 2 Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. https://t.me/ppdprogram

➡️Nayzilam (midazolam) Nasal Spray Date of Approval: May 17, 2019 Company: UCB Treatment for: Seizure Clusters Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters. https://t.me/ppdprogram

➡️Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) Extended-Release Tablets Date of Approval: May 2, 2019 Company: AstraZeneca Treatment for: Diabetes, Type 2 Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Duobrii (halobetasol propionate and tazarotene) Lotion Date of Approval: April 25, 2019 Company: Ortho Dermatologics Treatment for: Plaque Psoriasis Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis. https://t.me/ppdprogram

➡️Evenity (romosozumab-aqqg) Injection Date of Approval: April 9, 2019 Company: Amgen Inc. Treatment for: Osteoporosis Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. https://t.me/ppdprogram

➡️Duaklir Pressair (aclidinium bromide and formoterol fumarate) Inhalation Powder Date of Approval: March 29, 2019 Company: Circassia Pharmaceuticals plc Treatment for: COPD Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD. https://t.me/ppdprogram

➡️Sunosi (solriamfetol) Tablets Date of Approval: March 20, 2019 Company: Jazz Pharmaceuticals plc Treatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). https://t.me/ppdprogram

➡️Zulresso (brexanolone) Injection Date of Approval: March 19, 2019 Company: Sage Therapeutics Treatment for: Postpartum Depression Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD). https://t.me/ppdprogram

➡️Egaten (triclabendazole) Tablets Date of Approval: February 13, 2019 Company: Novartis Treatment for: Fascioliasis Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis, a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica. https://t.me/ppdprogram

➡️Wixela Inhub (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 30, 2019 Company: Mylan N.V. Treatment for: Asthma, COPD Wixela Inhub (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub is the first approved generic version of Advair Diskus. https://t.me/ppdprogram

➡️Gemtesa (vibegron) Tablets Date of Approval: December 23, 2020 Company: Urovant Sciences Treatment for: Overactive Bladder Gemtesa (vibegron) is a once-daily beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. https://t.me/ppdprogram

➡️Orgovyx (relugolix) Tablets Date of Approval: December 18, 2020 Company: Myovant Sciences Treatment for: Prostate Cancer Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer. https://t.me/ppdprogram

➡️Thyquidity (levothyroxine sodium) Oral Solution Date of Approval: November 30, 2020 Company: Vertice Pharma Thyquidity (levothyroxine sodium) is a liquid dosage form of levothyroxine for the treatment of hypothyroidism. https://t.me/ppdprogram

➡️Imcivree (setmelanotide) Injection Date of Approval: November 25, 2020 Company: Rhythm Pharmaceuticals, Inc. Treatment for: Obesity Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist for chronic weight management of obesity caused by proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency; or Bardet-Biedl syndrome. https://t.me/ppdprogram

➡️Oxlumo (lumasiran) Injection Date of Approval: November 23, 2020 Company: Alnylam Pharmaceuticals, Inc. Treatment for: Primary Hyperoxaluria Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. https://t.me/ppdprogram

➡️Sesquient (fosphenytoin sodium) for Injection Date of Approval: November 5, 2020 Company: Sedor Pharmaceuticals, LLC Treatment for: Status Epilepticus Sesquient (fosphenytoin sodium for injection) is a Captisol-enabled™, room-temperature stable formulation of fosphenytoin sodium indicated for the treatment of status epilepticus in adults and children. https://t.me/ppdprogram

➡️Bronchitol (mannitol) Inhalation Powder Date of Approval: October 30, 2020 Company: Chiesi USA, Inc. Treatment for: Cystic Fibrosis Bronchitol (mannitol) is an inhaled dry powder formulation of the sugar alcohol mannitol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. https://t.me/ppdprogram